The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling
Open accessAbstract
Virtual patients and digital patients/twins are two similar concepts gaining increasing attention in health care with goals to accelerate drug development and improve patients’ survival, but with their own limitations. Although methods have been proposed to generate virtual patient populations using mechanistic models, there are limited number of applications in immuno-oncology research. Furthermore, due to the stricter requirements of digital twins, they are often generated in a study-specific manner with models customized to particular clinical settings (e.g., treatment, cancer, and data types). Here, we discuss the challenges for virtual patient generation in immuno-oncology with our most recent experiences, initiatives to develop digital twins, and how research on these two concepts can inform each other.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“calibration requires data from diverse sources including targeted experimental studies and clinical endpoints2,3.”
From Structured Schemas for Provenance-Rich, LLM-Assisted QSP Model Calibration (2026) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“calibration requires data from diverse sources including targeted experimental studies and clinical endpoints [2, 3].”
From Structured Schemas for Provenance‐Rich, LLM ‐Assisted QSP Model Calibration (2026) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 1×
“In immuno-oncology, this is particularly challenging because: (1) the mechanisms involved in the cancer-immunity cycle 17,18 , including mechanism of action (MoA) of newly discovered therapeutics, are sometimes not fully understood (thus their effects are approximated by Hill functions rather than…”
BackgroundThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · cited 1×
“Withtheunprecedentedincreaseinomicsdataonspeci fi ccancertypes from collaborative studies, such as the TCGA 45 , AURORA 46 , Human Tumor Atlas Network (HTAN) 47 , and iAtlas 48 , it is possible to use the immune cell proportions derived from omics data for virtual patient generation.”
BackgroundLog-normal distributions across the sciences: keys and clues
LIMPERT, E., STAHEL, W. A., & ABBT, M. (2001) · BioScience · doi:10.1641/0006-3568(2001)051[0341:lndats]2.0.co;2 · Cited by 2,621
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585
Finotello, F., Mayer, C., Plattner, C., Laschober, G., Rieder, D., Hackl, H., Krogsdam, A., Loncova, Z., Posch, W., Wilflingseder, D., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0638-6 · Cited by 1,542 · cited 1×
“Usingimmunecelldeconvolution methods EPIC 50 and quanTIseq 51 , we were able to estimate the immune cell proportions and calculate the ratios of immune cell subset proportions betweenprimary breasttumorsand speci fi cmetastatic sites(e.g., lung, liver, and bone).”
MethodSimultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data
Racle, J., de Jonge, K., Baumgaertner, P., Speiser, D. E., & Gfeller, D. (2017) · eLife · doi:10.7554/elife.26476 · Cited by 1,384
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953 · cited 1×
“In immuno-oncology, this is particularly challenging because: (1) the mechanisms involved in the cancer-immunity cycle 17,18 , including mechanism of action (MoA) of newly discovered therapeutics, are sometimes not fully understood (thus their effects are approximated by Hill functions rather than…”
BackgroundDigital twins for health: a scoping review
Katsoulakis, E., Wang, Q., Wu, H., Shahriyari, L., Fletcher, R., Liu, J., Achenie, L., Liu, H., Jackson, P., Xiao, Y., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01073-0 · Cited by 760 · cited 1×
“On the other hand, health or medical digital twins are often developed for personalized medicine,which emphasize the correspondence with their physical counterparts in the real world 52 – 54 .”
BackgroundAlber, M., Buganza Tepole, A., Cannon, W. R., De, S., Dura-Bernal, S., Garikipati, K., Karniadakis, G., Lytton, W. W., Perdikaris, P., Petzold, L., et al. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0193-y · Cited by 639
How to tell the difference between a model and a digital twin
Wright, L., & Davidson, S. (2020) · Advanced Modeling and Simulation in Engineering Sciences · doi:10.1186/s40323-020-00147-4 · Cited by 601 · cited 2×
“Wrightand Davidson 57 discussed optimal properties of a model and data required tobuild digital twins.”
BackgroundMethod
Research works printed but not linked: 1
- Sorger, P. K. et al. Quantitative and systems pharmacology in the post‐genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. An NIH White Paper by the QSP Workshop Group (2011).
Cited by
From virtual to reality: innovative practices of digital twins in tumor therapy
Shen, S., Qi, W., Liu, X., Zeng, J., Li, S., Zhu, X., Dong, C., Wang, B., Shi, Y., Yao, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06371-z · Cited by 135
“Specifically, physiological data were widely applied in 16 studies, primarily used to dynamically adjust personalized treatment strategies [47, 61, 84].”
InfluentialExploring the Potential of Digital Twins in Cancer Treatment: A Narrative Review of Reviews
Giansanti, D., & Morelli, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103574 · Cited by 103
“[28] identified issues in generating spatially resolved generative digital twins, and [30] explored the difficulties in customizing immuno-oncology-specific models for patient treatment.”
InfluentialVallée, A. (2025) · Journal of Medical Internet Research · doi:10.2196/72411 · Cited by 94
“By aggregating anonymized DT data from populations, health care providers and researchers can identify emerging disease patterns, optimize resource allocation, and develop targeted intervention strategies [7,8].”
Digital Twins Generated by Artificial Intelligence in Personalized Healthcare
Łukaniszyn, M., Majka, Ł., Grochowicz, B., Mikołajewski, D., & Kawala‐Sterniuk, A. (2024) · Applied Sciences · doi:10.3390/app14209404 · Cited by 87
Chaparro-Cárdenas, S. L., Ramirez-Bautista, J. A., Terven, J. R., Esparza, D. M. C., Romero-González, J.-A., Ramírez-Pedraza, A., & Chávez‐Urbiola, E. A. (2025) · Healthcare · doi:10.3390/healthcare13141763 · Cited by 100
Metadata
- Authors
- Wang, H., Arulraj, T., Ippolito, A., & Popel, A. S.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Wang, Hanwen
- Venue
- npj Digital Medicine
- Published
- 2024-07-16
- Volume
- 7
- Issue
- 1
- Pages
- 189-189
- ISSN
- 2398-6352 (ISSN-L)
- PMC
- PMC11252162
- OpenAlex
- W4392575396
- Cited by
- 122
- References
- 67
- Citations by year
- 2026: 67 · 2025: 50 · 2024: 5
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Digital Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- arXiv (Cornell University) (submittedVersion)
- PubMed Central (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- arXiv (Cornell University)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA138264)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Keywords
- virtual patients, digital twin, cancer immunotherapy, quantitative systems pharmacology, mechanistic modeling, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling. https://app.cochat.ai/papers/10.1038/s41746-024-01188-4
- The paper
- Wang, H., Arulraj, T., Ippolito, A., & Popel, A. S. (2024). From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling. npj Digital Medicine. https://doi.org/10.1038/s41746-024-01188-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.